Ultragenyx Pharmaceutical’s (RARE) “Neutral” Rating Reiterated at Wedbush

Wedbush restated their neutral rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a report released on Tuesday,Benzinga reports. The firm currently has a $25.00 target price on the biopharmaceutical company’s stock.

Other research analysts have also issued research reports about the company. Leerink Partners reduced their price target on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Tuesday, December 30th. Wells Fargo & Company reduced their price target on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a report on Tuesday, December 30th. Guggenheim decreased their price target on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research note on Monday, January 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, January 21st. Finally, Jefferies Financial Group cut their price target on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a report on Tuesday, December 30th. Sixteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $68.29.

Ultragenyx Pharmaceutical Stock Performance

RARE opened at $21.83 on Tuesday. The company has a market cap of $2.11 billion, a price-to-earnings ratio of -3.74 and a beta of 0.16. The business’s fifty day moving average is $25.67 and its two-hundred day moving average is $29.54. Ultragenyx Pharmaceutical has a one year low of $18.41 and a one year high of $45.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 566.58%. The business had revenue of $207.28 million during the quarter, compared to analyst estimates of $199.60 million. During the same quarter in the prior year, the company earned ($1.39) earnings per share. The firm’s revenue for the quarter was up 25.5% compared to the same quarter last year. On average, analysts predict that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 3,061 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $23.56, for a total value of $72,117.16. Following the completion of the sale, the chief financial officer directly owned 88,935 shares in the company, valued at $2,095,308.60. The trade was a 3.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders sold 6,227 shares of company stock valued at $187,126. Insiders own 5.50% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently modified their holdings of RARE. Norges Bank bought a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at about $35,765,000. Hsbc Holdings PLC increased its holdings in shares of Ultragenyx Pharmaceutical by 88.6% in the second quarter. Hsbc Holdings PLC now owns 97,197 shares of the biopharmaceutical company’s stock worth $3,554,000 after acquiring an additional 45,665 shares in the last quarter. Skandinaviska Enskilda Banken AB publ raised its holdings in shares of Ultragenyx Pharmaceutical by 108.1% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 67,720 shares of the biopharmaceutical company’s stock worth $2,462,000 after acquiring an additional 35,185 shares during the period. Frazier Life Sciences Management L.P. lifted its holdings in shares of Ultragenyx Pharmaceutical by 49.3% in the second quarter. Frazier Life Sciences Management L.P. now owns 983,715 shares of the biopharmaceutical company’s stock valued at $35,768,000 after purchasing an additional 325,000 shares in the last quarter. Finally, Schroder Investment Management Group increased its position in shares of Ultragenyx Pharmaceutical by 27.2% in the second quarter. Schroder Investment Management Group now owns 336,173 shares of the biopharmaceutical company’s stock valued at $12,223,000 after acquiring an additional 71,888 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: HC Wainwright raised multiple 2026–2027 EPS forecasts, lifted several quarterly estimates and reiterated a Buy rating with a $50 price target — a bullish research view that supports potential upside if clinical/commercial execution meets their forecast. HC Wainwright coverage
• Neutral Sentiment: Canaccord cut its price target from $128 to $79 but kept a Buy rating; the lowered target reduces the analyst-implied upside even though the stance remains constructive. Canaccord note
• Neutral Sentiment: Wedbush reiterated a Neutral rating on RARE, providing little near‑term catalyst from that shop. Wedbush note
• Negative Sentiment: Multiple plaintiffs’ law firms have filed or are soliciting class members in a securities‑fraud suit (class period alleged: Aug 3, 2023–Dec 26, 2025) and are reminding investors of an April 6, 2026 lead‑plaintiff deadline. The filings allege material misstatements/omissions tied to setrusumab and create legal and settlement risk — a clear overhang that can pressure the stock while the case progresses. Representative notices: Pomerantz (PR Newswire), Robbins Geller (PR Newswire), Levi & Korsinsky (GlobeNewsWire). Pomerantz notice Robbins Geller notice Levi & Korsinsky notice

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.